Brief: Adaptimmune Therapeutics Believes Existing Cash, Cash Equivalents And Marketable Securities Will Fund Co’S Current Operations Into Late 2025
15/05/2024 12:47
May 15 (Reuters) - Adaptimmune Therapeutics PLC
ADAP.O :
* ADAPTIMMUNE THERAPEUTICS PLC -BELIEVES EXISTING CASH, CASH
EQUIVALENTS AND MARKETABLE SECURITIES WILL FUND CO’S CURRENT
OPERATIONS INTO LATE 2025
Source text for Eikon: ID:n0001558370-24-008210
Further company coverage: ADAP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adaptimmune Therapeutics
See all newsAdaptimmune Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 10 cents a share - Earnings Preview
Enters Settlement Agreement With MD Anderson - SEC Filing
Adaptimmune Therapeutics PLC reports results for the quarter ended March 31 - Earnings Summary
Adaptimmune Therapeutics PLC expected to post a loss of 12 cents a share - Earnings Preview